言語を選択

Complement C3

Complement C3 詳細

英語名	Complement C3	市販薬剤の数	1
治験薬の数	13	ターゲットの別称	Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b
研究＆開発段階	Approved

英語名	Complement C3
ターゲットの別称	Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b
市販薬剤の数	1
治験薬の数	13
研究＆開発段階	Approved

Complement C3 製品リスト

属性
Protein (5)Kits (1)
製品ライブラリ
オンライン (6)
種
Human (4)Mouse (1)Cynomolgus (1)
タグ
His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)- (1)
マーカー
Unconjugated (4)Biotin-labeled (1)- (1)

製品番号	種	発現システム	製品説明
HOT CO3-H52H3	Human	HEK293	Human Complement C3 Protein, His Tag, low endotoxin (MALS verified)
HOT CO3-H82E8	Human	HEK293	Biotinylated Human Complement C3 Protein, His,Avitag™ (MALS verified)
HOT CO3-M52H4	Mouse	HEK293	Mouse Complement C3 Protein, His Tag (MALS verified)
CEA-B263	Human	-	Human Complement C3 ELISA Kit
CO3-H5253	Human	HEK293	Human Complement component 3 Protein, Fc Tag (MALS verified)
CO3-C52H5	Cynomolgus	HEK293	Cynomolgus Complement C3 Protein, His Tag (MALS verified)

総数量6

Complement C3バックグランド

C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

Complement C3分子の別称

Complement C3,CPAMD1

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Efdamrofusp alfa	IBI-302	Phase 3 Clinical	AP Biosciences Inc	Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration	詳細
NGM-621	NGM-621	Phase 2 Clinical	NGM Biopharmaceuticals Inc	Coronavirus Disease 2019 (COVID-19); Geographic Atrophy	詳細
RG-002-C-0106	RG-002-C-0106; RG002C0106	Phase 2 Clinical	Beijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd	Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome	詳細
APL-3007	APL-3007	Phase 2 Clinical	Apellis Pharmaceuticals Inc	Geographic Atrophy	詳細
SGB-9768	SGB-9768	Phase 2 Clinical	Suzhou Sanegene Bio Inc	C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases	詳細
KRIYA-825	KRIYA-825; VV-14295	Phase 2 Clinical	Kriya Therapeutics Inc	Geographic Atrophy	詳細
ALXN-2030	ALXN-2030	Phase 2 Clinical	Alexion Pharmaceuticals Inc	Rejection of renal transplantation; Rejection of organ transplantation	詳細
LP-005	LP-005; RX-001	Phase 2 Clinical	Longbio Pharma (Suzhou) Co Ltd	Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies	詳細
ARO-C3	ARO-C3; ARO-C-3	Phase 2 Clinical	Arrowhead Pharmaceuticals Inc	C3 glomerulopathy; Glomerulonephritis, IGA	詳細
CG-001	CG-001	Phase 1 Clinical	Chengdu Konjin Co Ltd	Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis	詳細
BI-C		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Geographic Atrophy; Retinal Diseases	詳細
Ebribafusp alfa	ADX-097	Phase 1 Clinical	Q32 Bio Inc	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid	詳細
NM3086	NM3086; NM-3086	Phase 1 Clinical	NovelMed Therapeutics Inc	Hemoglobinuria, Paroxysmal	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Pegcetacoplan	APL-2	Approved	Apellis Pharmaceuticals Inc	Aspaveli, Empaveli, Syfovre	United States	Hemoglobinuria, Paroxysmal	Apellis Pharmaceuticals Inc	2021-05-14	Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation	詳細